Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro

Wu, Yi‐Cheng; Shen, Ya‐Ching; Chang, John Wen‐Cheng; Hsieh, Jia‐Juan; Chu, Yen; Wang, Cheng‐Hsu

doi:10.1016/j.cyto.2018.04.027

Cited by 25 publications

(21 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its expression is elevated in breast cancer [ 60 ], glioblastoma multiforme [ 61 ], and hepatocellular carcinoma [ 62 ]. In a tumor, CCL5 expression is found in cancer cells [ 63 , 64 ], cancer-associated fibroblasts (CAF) [ 65 ], mesenchymal stem cells (MSC) [ 66 ], MDSC [ 67 ], TAM [ 68 , 69 , 70 , 71 ], and TIL [ 72 ]. CCL5 expression also occurs in lymphatic endothelial cells, which is crucial for the formation of the metastatic niche [ 73 ].…”

Section: Ccr5 Ligandsmentioning

confidence: 99%

“…CCL5 acts on cancer cells by increasing their proliferation [ 62 , 64 , 74 , 75 ]. By activating the Wnt/β-catenin→signal transducer and activator of transcription 3 (STAT3) signaling pathways, it induces the self-renewal of prostate cancer stem cells [ 70 ].…”

Section: Ccr5 Ligandsmentioning

confidence: 99%

“…By activating the Wnt/β-catenin→signal transducer and activator of transcription 3 (STAT3) signaling pathways, it induces the self-renewal of prostate cancer stem cells [ 70 ]. Similar to other chemokines, CCL5 causes migration, invasion, and epithelial-to-mesenchymal transition (EMT) of cancer cells via its receptor [ 62 , 64 , 76 , 77 ], which is related to the activation of hedgehog [ 78 ], Wnt/β-catenin [ 70 , 79 ], and the Akt/PKB→nuclear factor κB (NF-κB) pathways [ 80 , 81 , 82 ]. The induction of migration by CCL5 is associated with increased secretion of matrix metalloproteinases (MMPs) by cancer cells [ 80 , 83 , 84 ].…”

Section: Ccr5 Ligandsmentioning

confidence: 99%

See 2 more Smart Citations

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands

Korbecki

Grochans

Gutowska

et al. 2020

IJMS

218

176

View full text Add to dashboard Cite

CC chemokines (or β-chemokines) are 28 chemotactic cytokines with an N-terminal CC domain that play an important role in immune system cells, such as CD4+ and CD8+ lymphocytes, dendritic cells, eosinophils, macrophages, monocytes, and NK cells, as well in neoplasia. In this review, we discuss human CC motif chemokine ligands: CCL1, CCL3, CCL4, CCL5, CCL18, CCL19, CCL20, CCL21, CCL25, CCL27, and CCL28 (CC motif chemokine receptor CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 ligands). We present their functioning in human physiology and in neoplasia, including their role in the proliferation, apoptosis resistance, drug resistance, migration, and invasion of cancer cells. We discuss the significance of chemokine receptors in organ-specific metastasis, as well as the influence of each chemokine on the recruitment of various cells to the tumor niche, such as cancer-associated fibroblasts (CAF), Kupffer cells, myeloid-derived suppressor cells (MDSC), osteoclasts, tumor-associated macrophages (TAM), tumor-infiltrating lymphocytes (TIL), and regulatory T cells (Treg). Finally, we show how the effect of the chemokines on vascular endothelial cells and lymphatic endothelial cells leads to angiogenesis and lymphangiogenesis.

show abstract

Section: Ccr5 Ligandsmentioning

confidence: 99%

Section: Ccr5 Ligandsmentioning

confidence: 99%

Section: Ccr5 Ligandsmentioning

confidence: 99%

See 1 more Smart Citation

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands

Korbecki

Grochans

Gutowska

et al. 2020

IJMS

218

176

View full text Add to dashboard Cite

show abstract

“…TAMs polarised into M2 macrophages by cytokines such as macrophage colony-stimulating factor (CSF1, M-CSF), IL-10, IL-13 and IL-4 produce anti-in ammatory cytokines such as TGF-β and IL-10 [43]. CCL5 and vascular cell adhesion molecule 1 (VCAM1) promote tumour progression and metastasis in ESCC [44,45]. Moreover, broblast growth factor-7 (FGF-7)…”

Section: Fgl2 May Promote the Initiation And Progression Of Esophageamentioning

confidence: 99%

Tumour-Associated Macrophage Polarisation Promotes Progression of Esophageal Carcinoma

Yuan

Zhang

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background: The immune response mediated by tumour-associated macrophages (TAMs) is vital in tumour progression in many cancers. Fibrinogen-like protein 2 (FGL2) is a critical immunosuppressive factor that regulates the tumour microenvironment. However, no study has yet reported on the relationship between FGL2, tumour-infiltrating lymphocyte recruitment, and prognosis in esophageal carcinoma (ESCA). Methods: Differentially expressed genes (DEGs) in various macrophage phenotypes were analysed using the GEO database. We identified the hub genes involved in affecting ESCA clinical prognosis using Kaplan-Meier plotter. Correlations between hub genes and immune infiltrates were analysed using the Tumour Immune Estimation Resource (TIMER) database, while correlation analysis between FGL2 and cytokine expression was assessed using cBioPortal. In vitro cell co-culture experiments were performed to examine the role of FGL2 in promoting tumorigenesis. Finally, we compared the GO terms and KEGG pathways enriched by the DEGs in M1 and M2 macrophages using DAVID.Results: High FGL2 expression was significantly associated with poorer overall survival and relapse-free survival of esophageal cancer patients. FGL2 expression was positively correlated with immune markers and infiltrating levels of B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and dendritic cells. In addition, FGL2 expression was strongly correlated to IL-10, MMP9, CCL5, TIM-3, IL-13, VCAM1, M-CSF and FGF-7 expression. Conclusions: M2-like TAMs may regulate the tumour microenvironment by secreting FGL2, thereby inducing the occurrence and progression of ESCA. Reversing TAM polarization may be an effective strategy that reveals new targets for immunotherapy in treating ESCA.

show abstract

“…CCL5 belongs to the CC family of chemokine and is mainly expressed in T cells, macrophages and some tumor cells 11 . Some researche had demonstrated that CCL5 promotes the development of malignant tumors including lung cancer, colorectal cancer, esophageal cancer, breast cancer and so on 12 - 15 . So CCL5 may be utilized as a biomarker to predict prognosis and act as a new target to treat KIRC.…”

Section: Introductionmentioning

confidence: 99%

The effect of CCL5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma

Bai¹,

Wu²,

Yan³

et al. 2020

Int. J. Med. Sci.

View full text Add to dashboard Cite

Background: Kidney renal clear cell carcinoma (KIRC) is the most representative subtype of renal cancer. Immune infiltration was associated with the survival time of patients with tumors. C-C chemokine ligand 5 (CCL5) can promote the malignant process of tumor and be related to infiltration immune cells in some cancers, but not reported in KIRC. Methods: The expression profile and clinical data were obtained from The Cancer Genome Atlas (TCGA) database. The correlation between the expression level of CCL5 and clinical features in KIRC was analyzed. Gene Set Enrichment Analysis (GSEA) was utilized to explore the functions and pathways of CCL5 in KIRC. Then, the analysis between the survival and immune infiltration cells was carried out, as well as the non-parametric tests between the CCL5 expression and the ratios of immune infiltration cells. Results: The correlations between the expression levels of CCL5 in KIRC and clinical features including survival time, pathological stage, grade, and status of the patient, have been identified. Meanwhile, GSEA analysis has shown relationships between the expression of CCL5 and immune pathways. The immune infiltrated cells were correlated with the prognosis of KIRC, especially regulatory T cells (Tregs), mast cells, and dendritic cells. And Tregs was associated with the CCL5 expression. Conclusion: The increased expression of CCL5 is related to poor prognosis and clinical features. Meanwhile, CCL5 is related to Tregs ratios and CCL5 may act as a typical chemokine to recruit Tregs in KIRC. CCL5 could be used as a biomarker for the prognosis prediction and a potential therapeutic target for patients with KIRC.

show abstract

Autocrine CCL5 promotes tumor progression in esophageal squamous cell carcinoma in vitro

Cited by 25 publications

References 34 publications

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands

CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands

Tumour-Associated Macrophage Polarisation Promotes Progression of Esophageal Carcinoma

The effect of CCL5 on the immune cells infiltration and the prognosis of patients with kidney renal clear cell carcinoma

Contact Info

Product

Resources

About